Best-in-class therapeutics
Leveraging proven mechanisms of action & next-generation novel compounds

PurMinds' science team is developing next generation therapeutics for neurological disorders by harnessing scientific rigor, leveraging strong strategic partnerships and developing an innovative approach to drug development with a focus on inducing neuroplasticity, reducing neuro-inflammation and promoting neuro-rejuvenation.  

 

We believe neuroplastogens and psychoplastogens offer new beacon of hope for Central Nervous System diseases, riding on exciting clinical data and recognition by regulatory bodies and the scientific community for psychiatric and neurological conditions where traditional therapies have largely failed. 

 

PurMinds’ small molecule programs (PUR501 and PUR400) are invented by our former Chief Scientific Officer, Dr. Alan Kozikowski, who is world renowned for his work in the area of medicinal chemistry designing NCEs for both cancer and CNS disorders, and in particular, in the areas of 5-HT and HDAC therapeutics. Our in-house formulation team has also developed proprietary psilocybin formulations for various indications.